Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

The outcome of surfactant replacement therapy in above nearterm neonates with severe pulmonary disease

준 만삭 이상아에서 폐표면 활성제 보충요법의 성적

  • Shon, Su-Min (Departments of Pediatrics, Keimyung University School of Medicine) ;
  • Lee, Bo-Young (Departments of Pediatrics, Keimyung University School of Medicine) ;
  • Kim, Chun-Soo (Departments of Pediatrics, Keimyung University School of Medicine) ;
  • Lee, Sang-Lak (Departments of Pediatrics, Keimyung University School of Medicine) ;
  • Kwon, Tae-Chan (Departments of Pediatrics, Keimyung University School of Medicine)
  • 손수민 (계명대학교 의과대학 소아과학교실) ;
  • 이보영 (계명대학교 의과대학 소아과학교실) ;
  • 김천수 (계명대학교 의과대학 소아과학교실) ;
  • 이상락 (계명대학교 의과대학 소아과학교실) ;
  • 권태찬 (계명대학교 의과대학 소아과학교실)
  • Received : 2007.10.10
  • Accepted : 2007.11.14
  • Published : 2007.12.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : We performed this study to investigate the outcome of surfactant replacement therapy (SRT) in above nearterm neonates who were required mechanical ventilatory care due to meconium aspiration pneumonia (MAP), respiratory distress syndrome (RDS) or other severe pneumonia (PN). Methods : 48 patients, gestational period ${\geq}36weeks$, who were admitted in NICU of Dongsan Medical Center, Keimyung University between July 1999 and June 2004 were enrolled. They were divided into three groups, MAP group (15 cases), RDS group (27 cases) and PN group (6 cases). All patients were received SRT and evaluated several clinical data (gestational age, oxygen index, duration of ventilator care) and outcome (complications and mortality rate) between pre-SRT and post-SRT. The mean dose of surfactant (modified bovine surfactant, Newfacten, Yuhan Co., Seoul, Korea) was 120 mg/kg. Results : Among each groups, mean pre-SRT OI was higher in MAP group ($21{\pm}3.2$) than other groups, mean duration (days) of ventilatory care and oxygen therapy were similar distributions. Compared with pre-SRT values, significant improvements (P<0.05) in mean values for FiO2 and oxygenation index were documented at 12 hours after SRT. Early complications (persistent pulmonary hypertension of newborm, pneumothorax) and survival rate were lower in MAP group. Within RDS group, earlier SRT (given before 12 hours of life) revealed significantly lower early complication rate than later SRT (given after 12 hours of life) (13.3% vs 58.3%, P<0.05) Conclusion : Our study suggested that SRT seems to be an effective therapy in above nearterm neonates with severe pulmonary disease, and earlier SRT tends to reduce complications in RDS group than later therapy.

목 적 : SRT는 주로 RDS이 있는 미숙아에서 시행되어 왔다. 저자들은 폐질환을 주소로 인공 환기 요법이 필요했던 재태 주령 36주 이상의 신생아에서 폐표면 활성제를 이용한 보충요법의 투여 성적를 알아보고자 본 연구를 시행하였다. 방 법 : 1999년 7월부터 2004년 6월까지 계명대학교 동산의료원 신생아 집중치료실에 입원한 후 폐질환을 주소로 인공 환기 요법을 받았던 재태 주령 36주 이상의 환아 중 SRT를 시행 받았던 48명의 환아를 대상으로 원인 질환에 따라 MAP군과 RDS군 그리고 PN군으로 나누어서 후향적으로 의무기록을 분석하였다. 모든 대상 환아들에서 SRT를 시행하였으며 폐표면 활성제(Newfacten: 유한양행, Seoul, Korea)는 120 mg을 생리식염수 2-4 mL에 용해하여 평균 120 mg/kg 용량으로 투여하였는데, RDS 군에서는 투여 6시간 후에도 임상적 호전이 미약할 때는 1회 더 투여하였다. 각 군에서 폐표면 활성제 사용 전 후의 임상지표(흡입 산소 농도 및 산소화 지수)와 폐표면 활성제 투여 시점으로부터의 총 인공 환기기 사용 및 산소 투여 기간을 알아보았으며 성적(합병증 및 생존율)를 분석하였다. 결 과 : 총 48례의 환아 중 MAP 군: 15명, RDS 군: 27명, PN 군: 6명 이었다. 폐표면 활성제 투여 전의 산소화 지수는 MAP 군이 $21.8{\pm}3.2$, RDS 군에서 $18.3{\pm}4.5$, PD 군에서 $18.6{\pm}6.0$였고, SRT 후 12시간째의 산소화 지수는 MAP 군이 $8.61{\pm}6.75$, RDS 군에서 $4.98{\pm}0.69$, PD 군에서 $5.8{\pm}1.19$로 통계적으로 유의하게 개선되었다(P<0.05). 총 인공 환기기 사용기간은 MAP 군이 $4.9{\pm}1.2$일, RDS 군이 $5.5{\pm}2.8$일, PN 군이 $7.2{\pm}4.8$일 이었고 산소 투여기간은 MAP 군이$9.4{\pm}1.7$일, RDS 군이 $8.8{\pm}3.5$일, PN 군이 $10.3{\pm}5.6$일 이었다. 기흉, 신생아 폐 고혈압 지속증 등의 합병증 발생은 MAP 군에서 20%, RDS 군에서 25.9%, PD 군에서 50%로 나타났으며, 이중 RDS 군에서 SRT를 처음 시행한 시간에 따른 합병증의 발생 정도는 생후 12시간 전에 시행한 경우의 발생률이 15례 중 2례(13.3%)로 12시간 이후에 시행한 경우의 12례 중 7례(58.3%) 보다 유의하게 낮았다(P<0.05). 생존율은 MAP 군이 86.7%, RDS군과 PN 군이 모두 100%로 모든 군에서 양호한 예후를 보였다. 결 론 : 중증 폐 질환을 주소로 인공 환기 요법이 필요한 임신기간 36주 이상의 준 만삭 이상아에서의 폐표면 활성제 보충요법은 좋은 임상경과를 가지며 특히 RDS인 경우 생후 12시간 내 투여가 합병증을 줄여서 치료성적의 향상에 도움이 될 것으로 사료된다.

Keywords

References

  1. Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child 1959;97:517-23
  2. Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T. Artificial surfactant therapy in hyaline membrane disease. Lancet 1980;1:55-9
  3. Namgung R, Lee C, Park KI. Exogenous Surfactant Replacement Therapy of Hyaline Membrane Disease : A controlled clinical trial. J Korean Pediatr Soc 1990;33:22-34
  4. Ramanathan R. Surfactant therapy in preterm infants with respiratory distress syndrome and in near-term or term newborns with acute RDS. J Perinatol 2006;26(suppl 1): S51-6 https://doi.org/10.1038/sj.jp.7211474
  5. El Shahed A, Dargaville P, Ohlsson A, Soll R. Surfactant for meconium aspiration syndromes in full term/near term infants. Cochrane Database Syst Rev 2007;18:CD002054
  6. Collaborative European Multicenter Study Group: Surfactant replacement therapy for severe neonatal respiratory distress syndrome : an international randomized clinical trial. Pediatrics 1988;82:683-91
  7. Gitlin JD, Soll RF, Parad RB, Horbar JD, Feldman HA, Lucey JF, et al. Randomized controlled trial of exogenous surfactant for the treatment of hyaline membrane disease. Pediatrics 1987;79:31-7
  8. Lang MJ, Hall RT, Reddy NS, Kurth CG, Merritt TA. A controlled trial of human surfactant replacement therapy for severe respiratory distress syndrome in very low birth weight infants. J Pediatr 1990;116:295-300 https://doi.org/10.1016/S0022-3476(05)82897-5
  9. Merritt TA, Hallman M, Bloom BT, Berry C, Benirschke K, Sahn D, et al. Prophylactic treatment of very premature infants with human surfactant. N Engl J Med 1986;315: 785-90 https://doi.org/10.1056/NEJM198609253151301
  10. Ten Center Study Group: Ten center trial of artificial surfactant (artificial lung expanding compound) in very premature babies. BMJ 1987;294:991-6 https://doi.org/10.1136/bmj.294.6578.991
  11. Soll RF, Hoekstra RE, Fangman JJ, Corbet AJ, Adams JM, James LS, et al. Multicenter trial of single-dose modified bovine surfactant extract(Survanta) for prevention of respiratory distress syndrome. Ross Collaborative Surfactant Prevention Study Group. Pediatrics 1990;85:1092-102
  12. Auten RL, Notter RH, Kendig JW, Davis JM, Shapiro DL. Surfactant treatment of full-term newborns with respiratory failure. Pediatrics 1991;87:101-7
  13. Khammash H, Perlman M, Wojtulewicz J, Dunn M. Surfactant therapy in full-term neonates with severe respiratory failure. Pediatrics 1993;92:135-9
  14. Glick PL, Leach CL, Besner GE, Egan EA, Morin FC, Malanowska- Kantoch A, et al. Pathophysiology of congenital diaphragmatic hernia III: Exogenous surfactant therapy for the high-risk neonate with CDH. J Pediatr Surg 1992;27: 866-9 https://doi.org/10.1016/0022-3468(92)90386-L
  15. Lotze A, Whitsett JA, Kammerman LA, Ritter M, Taylor GA, Short BL. Surfactant protein A concentrations in tracheal aspirate fluid from infants requiring extracorporeal membrane oxygenation. J Pediatr 1990;116:435-40 https://doi.org/10.1016/S0022-3476(05)82839-2
  16. Bui KC, Walther FJ, David-Cu R, Garg M, Warburton D. Phospholipid and surfactant protein A concentrations in tracheal aspirates from infants requiring extracorporeal membrane oxygenation. J Pediatr 1992;121:271-4 https://doi.org/10.1016/S0022-3476(05)81202-8
  17. Lotze A, Knight GR, Martin GR, Bulas DI, Hull WM, O'Donnell RM, et al. Improved pulmonary outcome after exogenous surfactant therapy for respiratory failure in term infants requiring extracorporeal membrane oxygenation. J Pediatr 1993;122:261-8 https://doi.org/10.1016/S0022-3476(06)80131-9
  18. Finer N. Surfactant use for neonatal lung injury: beyond respiratory distress syndrome. Paediatr Respir Rev 2004;5: S289-97 https://doi.org/10.1016/j.prrv.2004.07.006
  19. Sleight E, Coombs RC, Gibson AT, Primhak RA. Neonatal respiratory distress in near-term infants--consider surfactant protein B deficiency. Acta Paediatr 1997;86:428-30 https://doi.org/10.1111/j.1651-2227.1997.tb09037.x
  20. Chen CT, Toung TJ, Rogers MC. Effect of intra-alveolar meconium on pulmonary surface tension properties. Crit Care Med 1985;13:233-6 https://doi.org/10.1097/00003246-198504000-00005
  21. Moses D, Holm BA, Spitale P, Liu MY, Enhorning G. Inhibition of pulmonary surfactant function by meconium. Am J Obstet Gynecol 1991;164:477-81 https://doi.org/10.1016/S0002-9378(11)80003-7
  22. Sun B, Curstedt T, Song GW, Robertson B. Surfactant improves lung function and morphology in newborn rabbits with meconium aspiration. Biol Neonate 1993;63:96-104 https://doi.org/10.1159/000243917
  23. Sun B, Curstedt T, Robertson B. Surfactant inhibition in experimental meconium aspiration. Acta Paediatr 1993;82: 182-9 https://doi.org/10.1111/j.1651-2227.1993.tb12635.x
  24. Bae CW, Takahashi A, Chida S, Sasaki M. Morphology and function of pulmonary surfactant inhibited by meconium. Pediatr Res 1998;44:187-91 https://doi.org/10.1203/00006450-199808000-00008
  25. Cleary GM, Antunes MJ, Ciesielka DA, Higgins ST, Spitzer AR, Chander A. Exudative lung injury is associated with decreased levels of surfactant proteins in a rat model of meconium aspiration. Pediatrics 1997;100:998-1003 https://doi.org/10.1542/peds.100.6.998
  26. Herting E, Rauprich P, Stichtenoth G, Walter G, Johansson J, Robertson B. Resistance of different surfactant preparations to inactivation by meconium. Pediatr Res 2001;50:44-9 https://doi.org/10.1203/00006450-200107000-00010
  27. Lam BC, Yeung CY, Fu KH, Wong KY, Chan FL, Tsoi NS. Surfactant tracheobronchial lavage for the management of a rabbit model of meconium aspiration syndrome. Biol Neonate 2000;78:129-38 https://doi.org/10.1159/000014261
  28. Auten RL, Notter RH., Kendig JW, Davis JM, Shapiro DL. Surfactant treatment of full-term newborns with respiratory failure. Pediatrics 1991;87:101-7
  29. Halliday HL, Speer CP, Robertson B. Treatment of severe meconium aspiration syndrome with porcine surfactant. Collaborative Surfactant Study Group. Eur J Pediatr 1996;155:1047-51 https://doi.org/10.1007/BF02532529
  30. Kim CS, Lee SL, Kwon TC. The effect of surfactant lavage and replacement therapy in the neonates with meconium aspiration pneumonia (MAP). J Perinat Med 2003;31:S173-4
  31. Herting E, Sun B, Jarstrand C, Curstedt T, Robertson B. Surfactant improves lung function and mitigates bacterial growth in immature ventilated rabbits with experimentally induced neonatal group B streptococcal pneumonia. Arch Dis Child Fetal Neonatal Ed 1997;76:F3-8 https://doi.org/10.1136/fn.76.1.F3
  32. Herting E, Gan X, Rauprich P, Jarstrand C, Robertson B. Combined treatment with surfactant and specific immunoglobulin reduces bacterial proliferation in experimental neonatal group B streptococcal pneumonia. Am J Respir Crit Care Med 1999;159:1862-7 https://doi.org/10.1164/ajrccm.159.6.9810047
  33. Herting E, Gefeller O, Land M, Van Sonderen L, Harms K, Robertson B. Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. Members of the Collaborative European Multicenter Study Group. Pediatrics 2000;106:957-64 https://doi.org/10.1542/peds.106.5.957
  34. Fetter WP, Baerts W, Bos AP, Van lingen RA. Surfactant replacement therapy in neonates with respiratory failure due to bacterial sepsis. Acta Paediatr 1995;84:14-6 https://doi.org/10.1111/j.1651-2227.1995.tb13476.x
  35. Harms K, Herting E. Successful surfactant replacement therapy in two infants with ARDS due to chlamydial pneumonia. Respiration 1994;61:348-52 https://doi.org/10.1159/000196367
  36. Berk C, Grundy M. High risk lecithin/sphingomyelin ratios associated with neonatal diaphragmatic hernia. Case reports. Br J Obstet Gynecol 1982;89:250-1 https://doi.org/10.1111/j.1471-0528.1982.tb03626.x
  37. Bos AP, Tibboel D, Hazebroek FW, Molenaar JC, Lachmann B, Gommers D. Surfactant replacement therapy in high-risk congenital diaphragmatic hernia. Lancet 1991;338:1279
  38. Lotze A, Knight GR, Anderson KD, Hull WM, Whitsett JA, O'Donnell RM, et al. Surfactant (beractant) therapy for infants with congenital diaphragmatic hernia on ECMO: evidence of persistent surfactant deficiency. J Pediatr Surg 1994;29:407-12 https://doi.org/10.1016/0022-3468(94)90580-0
  39. Somaschini M, Locatelli G, Salvoni L, Bellan C, Colombo A. Impact of new treatments for respiratory failure on outcome of infants with congenital diaphragmatic hernia. Eur J Pediatr 1999;158:780-4 https://doi.org/10.1007/s004310051203
  40. Dubois A, Storme L, Jaillard S, Truffert P, Riou Y, Rakza T, et al. Congenital hernia of the diaphragm. A retrospective study of 123 cases recorded in the Neonatal Medicine Department, URHC in Lille between 1985 and 1996. Arch Pediatr 2000;7:132-42 https://doi.org/10.1016/S0929-693X(00)88082-3

Cited by

  1. 중증 태변흡입증후군의 임상적 특성 vol.51, pp.7, 2008, https://doi.org/10.3345/kjp.2008.51.7.713
  2. 중증 양수 흡인성 폐렴의 임상양상 및 폐표면 활성제 보충요법의 효과 vol.52, pp.4, 2007, https://doi.org/10.3345/kjp.2009.52.4.429
  3. Surfactant Therapy in Severe Meconium Aspiration Syndrome vol.20, pp.3, 2013, https://doi.org/10.5385/nm.2013.20.3.318